Vivos Therapeutics, Inc. Selling, General and Administrative Expense
Vivos Therapeutics, Inc. (VVOS) reported Selling, General and Administrative Expense of $500.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-12-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2022-12-20
- 2022-06-30: Selling, General and Administrative Expense 6 month $500.00K.
| Period end | Selling, General and Administrative Expense 6 month |
|---|---|
| 2022-06-30 | $500.00K 10-Q · filed 2022-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |